Pictet Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Pictet Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.6M	Sell	567,990 -13,093	-2%	-$1.37M	0.07%	275
2026 Q1	$61.2M	Buy	581,083 +51,452	+10%	+$4.56M	0.06%	274
2025 Q4	$46.3M	Sell	529,631 -292,581	-36%	-$23.9M	0.04%	341
2025 Q3	$54.6M	Buy	822,212 +70,235	+9%	+$3.99M	0.05%	311
2025 Q2	$41.6M	Buy	751,977 +456,384	+154%	+$21.9M	0.04%	346
2025 Q1	$14.3M	Sell	295,593 -918	-0.3%	-$38.5K	0.02%	571
2024 Q4	$11.4M	Buy	296,511 +289,213	+3,963%	+$12.6M	0.01%	624
2024 Q3	$328K	Buy	7,298 +1,450	+25%	+$58.6K	﹤0.01%	1560
2024 Q2	$203K	Buy	+5,848	New	+$171K	﹤0.01%	1760

Other funds holding PTGX

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Pictet Asset Management's PTGX Position: Q2 2026 in Review

Pictet Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 2.3% in Q2 2026, selling an estimated $1.37M and leaving 567,990 shares worth $69.6M. The position accounts for 0.07% of the portfolio, ranked #275.

Pictet Asset Management first reported a position in PTGX in Q2 2024 and has held it in 9 quarters since. 69 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Pictet Asset Management held 567,990 shares of Protagonist Therapeutics worth $69.6M as of Q2 2026.
Pictet Asset Management sold 13,093 Protagonist Therapeutics shares in Q2 2026, an estimated $1.37M.
Protagonist Therapeutics made up 0.07% of Pictet Asset Management's portfolio in Q2 2026, its #275 holding.
Pictet Asset Management first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 9 quarters since.
69 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.